Market Overview
Size, clinical need, and conversion
- Brevintel analysis values the U.S. female external catheter market at USD 306.8 million in 2025 ($307M), with expansion from USD 318.7 million in 2026 to USD 526.8 million by 2035 ($527M) at a 5.7% CAGR.
- Growth reflects a shift from absorbent products and indwelling catheters toward non-invasive collection that can support skin management, caregiver workflows, and catheter-avoidance protocols.
- Devices are worn externally around the urethral area and route urine to a drainage container without urethral insertion.
- Commercial relevance is strongest where incontinence is persistent, mobility is limited, or an indwelling catheter would create avoidable infection-control exposure.
- An estimated 61.8% of U.S. adult women, approximately 78.3 million individuals, experience urinary incontinence, with 32.4% reporting symptoms at least monthly and 9.8% reporting daily symptoms.
- The Urology Care Foundation separately estimates that urinary incontinence affects 30-40% of women.
- Becton Dickinson and Company led with over 60% market share in 2025, and the top five players collectively held 82%.
- Brevintel analysis finds the 5.7% path more selective than the clinical need pool, because conversion depends on documentation, discharge planning, and product-fit workflows.
Care settings and coverage
- Demand is uneven: among Medicare fee-for-service beneficiaries, incontinence prevalence reached 24.5% in home health, 20.6% in skilled nursing facilities, and 16.6% in nursing homes.
- Incontinent beneficiaries were also substantially more likely to experience urinary tract infections, dermatitis, and falls.
- Local Coverage Determination L33803 covers female external urinary collection devices as alternatives to indwelling catheters for beneficiaries with permanent urinary incontinence.
- Coverage is subject to documentation requirements and restrictions on concurrent indwelling-catheter use, so the category is not universally reimbursable for every leakage episode.
- Home health, skilled nursing, and nursing-home environments concentrate the heaviest operational burden where continence care intersects with skin protection, caregiver time, and infection exposure.
- Suppliers that demonstrate reliable urine capture and tolerability in institutional and home-based settings can participate in recurring disposable consumption.
- Products positioned only as convenience accessories may face weaker reimbursement conversion and lower clinician advocacy.
Market Dynamics
Clinical and protocol drivers
- Urinary incontinence enlarges the clinical population, but symptom severity and setting determine conversion into external-catheter demand.
- National Health and Nutrition Examination Survey data found stress urinary incontinence in 37.5% of affected women, mixed incontinence in 31.3%, and urgency incontinence in 22.0%.
- 22.1% of U.S. adult women had moderate-or-worse symptoms, with the commercial burden rising in home health and long-term care.
- Awareness supports adoption when incontinence is framed as a clinical management problem involving dignity, skin condition, mobility, and caregiver workload.
- Education is most commercially effective when embedded in discharge protocols, continence programs, and caregiver training rather than directed solely at consumers.
- Following female external urinary catheter introduction across nine ICUs, female catheter-associated urinary tract infection rates declined from 3.14 to 1.42 per 1,000 indwelling-catheter days.
- A broader meta-analysis found that protocol-adherent implementation was associated with a 54% reduction in catheter-associated urinary tract infection rates, although pooled significance was limited by study heterogeneity.
- In a nationally representative analysis of U.S. women, urgency and mixed urinary incontinence were most prevalent among women aged 60 years and older.
Restraints and adoption conditions
- External collection avoids urethral insertion but still requires skin assessment, fit verification, moisture management, and device-change discipline.
- In a 12-month multicenter catheterization trial, discontinuation was 39.0% with reusable products versus 26.6% with single-use products, with reduced ease of use and urethral irritation among reported reasons.
- That trial evaluated intermittent catheterization rather than female external catheters, so it is not direct product evidence, but it signals that tolerability and workflow friction can limit repeat use.
- Advanced external systems must justify procurement cost against absorbent alternatives, staff time, and avoided complications.
- Medicare coverage is available only within defined permanent-incontinence criteria and billing conditions, leaving access barriers outside that pathway.
- Agency for Healthcare Research and Quality data show that hospitalization costs associated with catheter-associated urinary tract infection can be materially higher than stays without the infection.
- Medicare analyses have identified additional costs and length of stay for ICU- and non-ICU-acquired cases, strengthening the purchasing case only when avoided-cost logic is documented.
- Brevintel analysis indicates the next adoption phase will be led by institutions that connect external-catheter use to a defined catheter-avoidance protocol rather than treating the product as a stand-alone supply item.
Segmentation Analysis
Product type
- Disposable products accounted for 92.4% of the market in 2025 and are projected to reach USD 492 million by 2035, expanding at a 5.9% CAGR.
- Dominance reflects infection-control preferences and the avoidance of cleaning, reprocessing, and cross-use uncertainty in hospitals, post-acute facilities, and home-care settings.
- Single-use formats also fit recurring supply models and can reduce the training burden associated with maintenance.
- Reusable products generated USD 23.2 million in 2025, where durability and lower replacement frequency are valued.
- Reusable adoption is constrained by cleaning requirements and the risk that convenience declines over time.
- Compliance evidence from reusable catheterization products reinforces the commercial advantage of designs that minimize patient handling and maintenance complexity.
Incontinence type
- Overactive bladder and urge incontinence represented USD 128.5 million in 2025, making this the leading incontinence-type segment.
- Urgency and mixed urinary incontinence rise in older age groups, aligning the segment with Medicare beneficiaries, home-health patients, and residents of skilled care environments.
- Users often need a non-invasive option during limited mobility, overnight care, or frequent urgency, so demand can be episodic but recurrent.
- Stress urinary incontinence accounted for USD 96.1 million in 2025, with greater emphasis on discretion, mobility, and secure fit during daily activities.
- External collection can serve selected stress-incontinence users who need active urine management, provided bulk or attachment issues do not conflict with ambulatory use.
- Other incontinence types include mixed, functional, overflow, and condition-specific presentations that reward patient-selection protocols rather than a single device configuration.
Material
- Silicone generated USD 122.6 million in 2025 and is expected to outpace latex as material choice increasingly reflects skin compatibility and infection-control priorities.
- Silicone flexibility and a non-allergenic profile support prolonged skin contact.
- Clinical catheter studies have found lower bacterial colonization and biofilm-forming properties for pure silicone than silicone-coated latex.
- Latex accounted for USD 88.5 million in 2025 and retains relevance where elastic fit and lower material cost are priorities, particularly for shorter-duration use.
- A review of 26 clinical studies associated siliconised latex with higher urinary tract infection risk and noted that latex should be avoided where allergy risk is relevant.
- The same review identified greater bacterial adherence potential associated with latex hydrophobic properties.
- PVC and other materials serve narrower design, cost, and durability requirements, with potential tied to differentiated fit, fluid handling, comfort, or disposal characteristics.
Application and end use
- Urinary incontinence accounted for USD 105.7 million in 2025 and remains the category central application, tied to recurrent leakage management in inpatient, post-acute, and home-care settings.
- Urinary retention represented USD 73.7 million in 2025; external systems do not resolve retention itself but may support selected patients with concomitant leakage or temporary management needs.
- Post-surgical recovery generated USD 61.4 million in 2025, where temporary immobility, anesthesia recovery, or early discharge creates a need for hygienic urine management.
- Neurological disorders and other applications are shaped by functional dependence, repeated care needs, and caregiver burden, requiring careful fit assessment.
- Hospitals held a 45.2% share in 2025, reflecting catheter-avoidance initiatives, perioperative care, patient immobility, and infection-prevention accountability.
- Ambulatory surgical centers generated USD 77.2 million in 2025, favoring products that can be applied and removed quickly while supporting recovery-area hygiene.
- Specialty clinics, home-care providers, and long-term care facilities are important routes to sustained use because incontinence care is recurrent and tied to caregiver workload.
- Brevintel analysis estimates commercial gravity where single-use convenience, older-age urgency burden, and skin-compatible materials converge, with disposables at 92.4%, overactive bladder at USD 128.5 million, and silicone at USD 122.6 million.
Regional Outlook
South Atlantic, Northeast, and Pacific Central
- The South Atlantic region accounted for 21% of the U.S. market in 2025 and generated USD 64.5 million.
- Scale reflects an aging population, large retirement communities, and substantial demand for home-based and long-term continence care.
- The South also carried the largest absolute burden of overactive bladder cases among Medicare fee-for-service beneficiaries in the referenced regional analysis, at 915,091 cases.
- The Northeast generated USD 52 million in 2025 and combined dense health-system infrastructure with the highest overactive bladder prevalence in that analysis, at 8.4% and approximately 508,500 cases.
- Medicare coverage for qualifying permanent urinary incontinence creates a relevant reimbursement pathway across the Northeast.
- Pacific Central generated USD 62.6 million in 2025, supported by an advanced provider base and concentration of medical-technology adoption.
- Regional utilization evidence shows that non-ICU indwelling-catheter utilization was highest in the West among the four broad U.S. regions assessed, indicating a catheter-substitution opportunity where appropriate.
- Brevintel analysis sees South Atlantic as a care-continuum coverage priority, the Northeast as a reimbursement and account-concentration opportunity, and Pacific Central as an evidence-intensive workflow play.
Other census divisions
- East North Central demand is supported by hospital systems, post-acute providers, and aging populations across Illinois, Indiana, Michigan, Ohio, and Wisconsin.
- Utilization there is likely to be shaped by institutional catheter-reduction initiatives and the ability to standardize external-device protocols across acute and post-acute settings.
- West South Central demand is influenced by large and geographically dispersed care networks across Texas, Oklahoma, Arkansas, and Louisiana, where home health, long-term care, and hospital discharge pathways matter.
- East South Central demand is anchored in hospital, skilled nursing, and home-care needs across Alabama, Kentucky, Mississippi, and Tennessee, with uptake depending on practical value for budget-sensitive facilities.
- The West North Central market is dispersed across metropolitan and rural environments, elevating distributor reach, replenishment, and straightforward caregiver instruction.
- Mountain States demand is shaped by lower population density, urban referral centers, rural facilities, and the need for reliable access across dispersed geographies.
- Products that are easy to train, deliver, and reorder are likely to have greater commercial relevance in geographically dispersed divisions than highly specialized systems requiring intensive onsite support.
- Brevintel analysis concludes that regional concentration reflects more than population size: manufacturers that win a hospital account but lack home-health and long-term-care fulfillment risk losing recurrent disposable demand after discharge.
Competitive Landscape
Structure
- Competition is shaped by product comfort, urine-capture reliability, skin compatibility, infection-control positioning, clinical education, and distribution reach.
- Becton Dickinson and Company led with over 60% market share in 2025, and the top five collectively held 82%.
- Established suppliers benefit from hospital relationships and supply-chain access, while specialized participants can differentiate through fit, material innovation, or focused care-setting strategies.
- Becton Dickinson and Company is positioned through clinical product innovation, hospital penetration, clinician relationships, and integrated urinary-management capabilities.
- Stryker PrimaFit is positioned around external urine management for female patients in acute-care environments.
- Product updates announced in January 2022 included longer flexible tubing, an additional 14% of ultra-soft fabric, and a tapered end.
- Wellspect HealthCare expanded its U.S. female external catheter presence with the January 2026 launch of the Surity Female External Catheter.
- Medline distribution across acute, post-acute, and long-term care is strategically relevant to disposable adoption and replenishment.
- Hollister position is supported by patient-centered design, comfort-oriented materials, education-led adoption, and relevance in home healthcare and specialty-care channels.
- Consure Medical, Boehringer, Tilla Care, and Ur24Technology compete through differentiated continence concepts, targeted innovation, and focused category participation.
Hospital and integrated suppliers
- Becton Dickinson and Company
- Stryker
- Medline
- Wellspect HealthCare
Specialty continence suppliers
- Hollister
- Boehringer
- Consure Medical
- Tilla Care
- Ur24Technology